Cannabis And Pregnancy: What The Medical Authorities Say

Cannabinoids cross the placenta. THC, CBD, and other cannabinoids in maternal circulation reach the fetus through the placental circulation. The fetal endocannabinoid system plays roles in early brain development, neuron migration, and the formation of neural connections. Disrupting that system during a critical developmental window is the concern that drives the medical recommendation.

Research in animal models and observational human studies has documented several specific concerns.

Lower birth weight. Studies including large observational cohort analyses have associated prenatal cannabis exposure with reduced birth weight. Lower birth weight correlates with increased risk of complications in the newborn period and longer-term developmental considerations.

Preterm birth. Some studies have found increased risk of preterm delivery with cannabis use during pregnancy, with the strongest association in heavier-use patterns.

Neurodevelopmental outcomes. Observational studies have associated prenatal cannabis exposure with attention, cognition, executive function, and behavior differences in childhood and adolescence. Causation is difficult to establish in observational data because cannabis use during pregnancy is correlated with other variables (socioeconomic factors, other substance exposures, nutrition) that also affect outcomes. Multiple studies controlling for these confounders still find association, which is part of why the medical authority recommendation has not softened.

Breast milk transfer. Cannabinoids appear in breast milk for hours to days after maternal consumption, and the cannabinoids are fat-soluble, which extends their presence in breast tissue. A breastfeeding infant receives the cannabinoid exposure through nursing, with potential neurodevelopmental implications given the rapid brain development of the first year of life.

The strength of evidence varies across these outcomes. Birth weight and preterm birth findings are better-documented than the long-term neurodevelopmental findings. The consistent medical authority recommendation reflects the precautionary principle applied to the full evidence picture.

A meaningful minority of pregnant individuals use cannabis during pregnancy. Survey data and clinical observation document several reasons.

Severe nausea and vomiting (hyperemesis gravidarum). Severe pregnancy-related nausea that does not respond to standard antiemetic medications like ondansetron or doxylamine-pyridoxine. Some patients find cannabis helpful when other options fail. The condition can be debilitating and the cannabis-versus-alternative-treatment conversation is worth having with the obstetric provider rather than as a self-managed choice.

Anxiety and stress. Pregnancy can intensify anxiety, depression, or pre-existing mental health conditions. Some patients use cannabis as an alternative to anti-anxiety medications that carry their own pregnancy considerations (benzodiazepines, SSRIs in certain trimesters). The clinical answer is not always obvious because every treatment option in pregnancy involves a benefit-versus-risk calculation; the medical authority position is that cannabis is not the preferred option.

Chronic pain. Patients with pre-pregnancy chronic pain conditions may continue cannabis use during pregnancy. The pain management conversation during pregnancy involves several options and the obstetric provider is the right interlocutor.

Sleep difficulties. Some patients use cannabis for pregnancy-related insomnia, which is common in the third trimester. Non-pharmacological sleep strategies and provider-recommended options are the medical authority preference.

Lack of awareness. Some patients are unaware of the medical authority recommendations or have heard mixed messages. The medical authority position is clear and consistent.

The medical authority position across these use cases is that other treatment options should be tried first, that cannabis should be avoided when possible, and that any cannabis use during pregnancy should be discussed with the obstetric provider rather than self-managed. The conversation between patient and provider is the right place for the specific calculation that fits a specific case.

New York State licensed dispensaries do not knowingly sell to pregnant individuals. NYS regulation requires dispensary staff to refrain from sale when a pregnancy is disclosed or apparent. The Alchemy and other NYS-licensed dispensaries follow this requirement consistently.

In practice, dispensary staff do not ask customers whether they are pregnant. If a customer voluntarily discloses pregnancy during a consultation or makes the pregnancy apparent, the budtender will gently decline the sale and refer the customer to their obstetric provider and to the resources listed below. The decline is not a moral judgment; it is a regulatory and ethical position consistent with the medical authority consensus.

NYS-licensed dispensaries do not provide medical advice about cannabis use during pregnancy. Customers with pregnancy-related questions are referred to obstetric providers and to the medical authorities listed above.

Your obstetric provider. The most important resource for any pregnancy-related cannabis question. The provider knows your specific medical situation, your medication list, your trimester, your prior pregnancy history, and the specific clinical considerations that apply to your case. The conversation is confidential under standard medical privacy rules.

MotherToBaby. A non-profit resource for evidence-based information about exposures during pregnancy and breastfeeding, run by the Organization of Teratology Information Specialists. Free counseling by phone and chat with trained teratology information specialists. mothertobaby.org

NYS Medical Cannabis Program. For patients with serious medical conditions for whom cannabis is being considered, the NYS medical program offers consultation with registered practitioners who can advise on risks and benefits in specific medical contexts. Medical cannabis patients with pregnancy considerations should discuss the situation with the medical practitioner who issued the certification.

NYC Department of Health and Mental Hygiene. Local resources for pregnancy support, prenatal care, and substance use counseling. The Department's pregnancy and parenting hub provides a starting point.

1-800-MOTHERS (NYC). NYC resource for pregnant individuals seeking support including substance use counseling. Free, confidential.

NYS Poison Control 1-800-222-1222. For accidental cannabis exposure during pregnancy or for any questions about cannabis exposure in pregnancy or breastfeeding. 24-hour staffed line.

SAMHSA National Helpline 1-800-662-4357. Free, confidential, 24-hour treatment referral and information service for substance use questions.

For postpartum individuals considering returning to cannabis use, the breastfeeding consideration extends the medical authority recommendation for the duration of breastfeeding. Cannabinoids appear in breast milk for hours to days after consumption and the cannabinoids are fat-soluble, which extends their presence in breast tissue. The breastfeeding infant receives the exposure.

Once breastfeeding ends or if the individual is not breastfeeding, the medical authority recommendation no longer applies in the same way. Postpartum individuals can resume adult-use cannabis on the same legal basis as any adult 21 and over.

Many postpartum individuals find low-dose CBD-balanced products useful for postpartum stress and sleep support, and the cannabis purchase patterns we see from postpartum customers at The Alchemy typically lean toward 1:1 or 2:1 CBD-to-THC ratios at low total doses (2.5 to 5 mg THC) rather than high-THC products. Postpartum mood considerations including postpartum depression and postpartum anxiety remain a medical conversation worth having with the obstetric provider or a mental health professional.

Is CBD safe during pregnancy?

The FDA recommends against any cannabinoid use during pregnancy, including CBD. CBD crosses the placenta and the breastfeeding implications are similar to other cannabinoids. The position covers both hemp-derived CBD products and cannabis-derived CBD products. Consult your obstetric provider for personalized guidance.

What if I used cannabis before knowing I was pregnant?

Discuss the timing and use pattern with your obstetric provider. Many pregnancies proceed normally even with early exposure before pregnancy was known. Your provider can address specific concerns about your case, monitor as appropriate, and provide guidance going forward. The conversation is confidential.

Can I use cannabis to manage morning sickness or hyperemesis gravidarum?

Medical authorities recommend other antiemetics first (vitamin B6, doxylamine, ondansetron, IV fluids for severe cases). Some patients with severe refractory hyperemesis discuss cannabis with their provider as a last-resort option after standard treatments have failed. Self-managing severe pregnancy nausea with cannabis without medical consultation is not recommended; severe hyperemesis is a serious condition that benefits from clinical care.

How long should I abstain before getting pregnant?

Medical authorities recommend cannabis discontinuation before conception. The specific timeframe varies by individual circumstance; ask your obstetric or fertility provider for the recommendation that fits your situation. Both individuals contributing to a conception may have reasons to consider their cannabis use; the conversation is worth having before trying to conceive.

What if my partner uses cannabis around me during pregnancy?

Secondhand cannabis smoke exposure during pregnancy is also a concern, similar to secondhand tobacco smoke. Minimize cannabis smoke and vapor exposure in shared living spaces during pregnancy. Edibles or other non-combustible formats avoid the secondhand exposure issue but the partner-pregnancy support conversation is still worth having.

Does NYS prohibit dispensaries from selling to pregnant individuals?

NYS regulation requires dispensary staff to refrain from sale when pregnancy is disclosed or apparent. Dispensary staff do not ask about pregnancy proactively. If pregnancy is disclosed or apparent, the budtender will decline the sale and refer the customer to medical and counseling resources.

Are there long-term studies of children exposed to cannabis in utero?

Yes, several. The findings are mixed but the body of evidence has driven the consistent medical authority recommendation against cannabis use during pregnancy. The strongest documented associations are with birth weight and preterm birth; the neurodevelopmental findings are weaker but persistent across multiple controlled analyses.

Can I use cannabis topicals (creams, balms) during pregnancy?

Topical absorption of cannabinoids through intact skin is generally limited. The FDA recommendation still covers any cannabinoid product including topicals because absorption can vary and the safety data for pregnancy-specific use is absent. Consult your obstetric provider before using any cannabinoid product including topicals.

Where can I get free, confidential help if I am struggling with cannabis use during pregnancy?

MotherToBaby (mothertobaby.org), SAMHSA National Helpline at 1-800-662-4357, NYC Department of Health and Mental Hygiene resources, and your obstetric provider are all confidential resources. The conversation does not generate a report to child welfare authorities except in specific circumstances that vary by case.